Multiple Myeloma Clinical Trial
Official title:
A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TTI-622 (PF-07901801), A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED OR REFRACTORY LYMPHOMA
| Verified date | March 2024 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this clinical trial is to learn about how safe and tolerable is the study medicine (called maplirpacept (PF-07901801)) when taken for the treatment of lymphoma or multiple myeloma (a type of cancer that affects your body's infection-fighting cells, lymphocytes or plasma cell). This study is seeking participants who: - are 18 years of age or older - have worsening and difficult to manage type of lymphoma or multiple myeloma - Have adequately functioning organs - are not on long term use of steroids which are given either by mouth or as shots - have no major heart related disease etc. All participants in this study will receive maplirpacept (PF-07901801) as an IV infusion (given directly into a vein) at the study clinic every week. Participants will continue to receive maplirpacept (PF-07901801) until their progress of cancer worsens or the participants do not wish to take the study medicine. The experiences of the people receiving the study medicine will be collected. This will help to understand if the study medicine maplirpacept (PF-07901801), is safe and can be given to Japanese people.
| Status | Active, not recruiting |
| Enrollment | 7 |
| Est. completion date | July 10, 2024 |
| Est. primary completion date | July 10, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Relapsed or refractory lymphoma (Hodgkin's or non-Hodgkin's) or multiple myeloma - Disease must have progressed with standard anticancer therapies - measurable disease - Capable of giving signed informed consent - Eastern cooperative oncology group performance status 0 or 1 - Adequate organ functions Exclusion Criteria: - Known, current central nervous system or interstitial lung disease involvement - History of hemolytic anemia or positive direct antiglobulin test or active bleeding disorder - Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent - Significant cardiovascular disease - Other significant medical condition unrelated to the primary malignancy - Radiation therapy within 14 days of study treatment administration - Hematopoietic stem cell transplant within 90 days before the planned start of study treatment - Antiplatelet/anticoagulant agents within 14 days before planned start of study treatment - Patients sustaining major surgery at least 4 weeks prior to study enrollment - Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment - Prior anti-CD47 and anti-Signal Regulatory Protein alpha therapy - Active, uncontrolled bacterial, fungal, or viral infection - Investigator site staff directly involved in the conduct of the study and their family members |
| Country | Name | City | State |
|---|---|---|---|
| Japan | Japanese Foundation for Cancer Research | Koto | Tokyo |
| Japan | The Cancer Institute Hospital of JFCR | Koto | Tokyo |
| Japan | Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital | Nagoya | Aichi |
| Japan | Yamagata University Hospital | Yamagata |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants with Dose Limiting Toxicity (DLT) in lymphoma | Number of participants with DLTs | up to 21 days | |
| Secondary | Number of adverse events as characterized by type | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of adverse events as characterized by frequency | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of adverse events as characterized by severity | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of adverse events as characterized by timing | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of adverse events as characterized by relationship to maplirpacept (PF-07901801) | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of adverse events as characterized by seriousness | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of participants with clinically significant change from baseline in laboratory abnormalities as characterized by type | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of participants with clinically significant change from baseline in laboratory abnormalities as characterized by frequency | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of participants with clinically significant change from baseline in laboratory abnormalities as characterized by severity | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of participants with clinically significant change from baseline in laboratory abnormalities as characterized by timing | overall safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Number of participants with severe thrombocytopenia and anemia in R/R multiple myeloma | overll safety profile of maplirpacept (PF-07901801) | Through study completion, up to 18 monghs | |
| Secondary | maximum observed concentration, steady state (ss) of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | time to maximum concentration,ss of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | area under the curve last,ss of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | area under the curve tau,ss of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | time to maximum concentration of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | trough concentration of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | area under the curve last of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | clearance of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | area under the curve tau of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | volume of distribution at steady-state of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | area under the curve tau,ss/area under the curve tau,sd of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | area under the curve inf of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | terminal elimination half-life off maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | maximum observed concentration of maplirpacept (PF-07901801) | pharmacokinetics of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Incidence and titers of anti-drug antibodies against maplirpacept (PF-07901801) | immunogenicity of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | Incidence and titers of neutralizing antibodies against maplirpacept (PF-07901801) | immunogenicity of maplirpacept (PF-07901801) | Through study completion, up to 18 months | |
| Secondary | overall response rate | preliminary antitumor activity of maplirpacept (PF-07901801) | From date of registration until the date of first documented progression or date of death from any cause, cause, whichever comes first, assessed up to 18 months | |
| Secondary | progression free survival | preliminary antitumor activity of maplirpacept (PF-07901801) | From date of registration until the date of first documented progression or date of death from any cause, cause, whichever comes first, assessed up to 18 months | |
| Secondary | time to response | preliminary antitumor activity of maplirpacept (PF-07901801) | From date of registration until the date of first documented progression or date of death from any cause, cause, whichever comes first, assessed up to 18 months | |
| Secondary | duration of response | preliminary antitumor activity of maplirpacept (PF-07901801) | From date of registration until the date of first documented progression or date of death from any cause, cause, whichever comes first, assessed up to 18 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |